Cue Biopharma, Inc. Other Comprehensive Income (Loss), Net of Tax
Cue Biopharma, Inc. (CUE) reported Other Comprehensive Income (Loss), Net of Tax of $259.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2020-05-07
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2020-03-31 was $259.00K, a 3137.50% increase year-over-year.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2019-12-31 was -$10.36K.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2019-09-30 was $0.00.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax for the quarter ending 2019-06-30 was $3.00K.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax for fiscal 2019 was $637.00.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax for fiscal 2018 was -$10.96K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2020-03-31 | $259.00K 10-Q · filed 2020-05-07 | $248.64K derived: sum of 2 quarters · filed 2020-05-07 | $248.64K derived: sum of 3 quarters · filed 2020-05-07 | $251.64K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | -$10.36K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$10.36K derived: sum of 2 quarters · filed 2020-03-12 | -$7.36K derived: sum of 3 quarters · filed 2020-03-12 | $637.00 10-K · filed 2020-03-12 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $3.00K derived: sum of 2 quarters · filed 2019-11-07 | $11.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.00K 10-Q · filed 2019-08-08 | $11.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $8.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$10.96K 10-K · filed 2020-03-12 | |||
| 2018-09-30 | -$20.00K 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |